Evidence map›Paper›PMID 34812561›Full record

Trial reportJournal of the European Academy of Dermatology and Venereology : JEADV2022

Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial.

C Ryan, L Guenther, P Foley, J Weisman, R T Burge, G Gallo, K See, M McKean-Matthews, C C Bertram, J F Merola

Open access · bronzeAbstract readClinical Trial, Phase IIILetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the European Academy of Dermatology and Venereology : JEADV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Updates on Psoriasis in Special Areas.Journal of clinical medicine · 2024
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

C RyanCharles Institute of Dermatology, University College, Dublin, Ireland.ORCID https://orcid.org/0000-0003-1915-546X
L GuentherGuenther Dermatology Research Centre, London, ON, Canada.
P FoleySkin Health Institute, Melbourne, VIC, Australia.
J WeismanMedical Dermatology Specialists, Atlanta, GA, USA.
R T BurgeEli Lilly and Company, Indianapolis, IN, USA.
G GalloEli Lilly and Company, Indianapolis, IN, USA.
K SeeEli Lilly and Company, Indianapolis, IN, USA.
M McKean-MatthewsSyneos Health, Raleigh, NC, USA.
C C BertramEli Lilly and Company, Indianapolis, IN, USA.
J F MerolaHarvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0001-6514-4353
Eli Lilly (United States) · USDermatology Specialists · USGuenther Dermatology Research Centre · CAHarvard University · USSkin Health Institute · AUSyneos Health (United States) · USUniversity College Dublin · IE

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Dermatologic AgentsPsoriasisAdultAntibodies, Monoclonal, HumanizedDouble-Blind MethodGenitaliaHumansQuality of LifeSeverity of Illness IndexTreatment OutcomeAntibodies, Monoclonal, HumanizedDermatologic Agentsixekizumab

Identifiers

PMID34812561
PMCPMC9299771
OpenAlexW3215006483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.